ATE445701T1 - Zytokine rezeptor zcytor19 - Google Patents

Zytokine rezeptor zcytor19

Info

Publication number
ATE445701T1
ATE445701T1 AT01988203T AT01988203T ATE445701T1 AT E445701 T1 ATE445701 T1 AT E445701T1 AT 01988203 T AT01988203 T AT 01988203T AT 01988203 T AT01988203 T AT 01988203T AT E445701 T1 ATE445701 T1 AT E445701T1
Authority
AT
Austria
Prior art keywords
polypeptides
zcytor19
methods
cytokine receptor
vitro
Prior art date
Application number
AT01988203T
Other languages
English (en)
Inventor
Scott Presnell
Wenfeng Xu
Julia Novak
Theodore Whitmore
Francis Grant
Original Assignee
Zymogenetics L L C
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics L L C, Bristol Myers Squibb Co filed Critical Zymogenetics L L C
Application granted granted Critical
Publication of ATE445701T1 publication Critical patent/ATE445701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
AT01988203T 2000-11-28 2001-11-28 Zytokine rezeptor zcytor19 ATE445701T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US26721101P 2001-02-07 2001-02-07
PCT/US2001/044808 WO2002044209A2 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Publications (1)

Publication Number Publication Date
ATE445701T1 true ATE445701T1 (de) 2009-10-15

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988203T ATE445701T1 (de) 2000-11-28 2001-11-28 Zytokine rezeptor zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (de)
EP (1) EP1356046B1 (de)
JP (1) JP2004532611A (de)
AT (1) ATE445701T1 (de)
AU (1) AU2002241533A1 (de)
CA (1) CA2430485A1 (de)
CY (1) CY1110921T1 (de)
DE (1) DE60140213D1 (de)
DK (1) DK1356046T3 (de)
ES (1) ES2334888T3 (de)
PT (1) PT1356046E (de)
WO (1) WO2002044209A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP1497415B1 (de) * 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
BRPI0613859B8 (pt) 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
EP1845097A1 (de) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazolderivate als COMT Inihibitoren
EP2124947B1 (de) 2007-01-31 2017-07-19 BIAL - Portela & Ca., S.A. Dosierschema für comt-hemmer
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
CN105878242A (zh) * 2009-04-01 2016-08-24 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
CN102438595B (zh) * 2009-04-01 2016-04-27 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN103732610A (zh) * 2011-06-13 2014-04-16 默沙东公司 纯化天然或突变体形式的白喉毒素的方法
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
JP2016519070A (ja) * 2013-03-15 2016-06-30 アッヴィ・インコーポレイテッド 抗体薬物複合体（ａｄｃ）の精製
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN109641037B (zh) * 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1194549A2 (de) 1999-07-02 2002-04-10 Chiron Corporation Menschliche gene und gen expressionsprodukte
CN1452633A (zh) * 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
CN101531715A (zh) * 2001-04-20 2009-09-16 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
CA2462687A1 (en) 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
EP1497415B1 (de) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand
EP1575609A4 (de) 2002-10-23 2010-12-15 Zymogenetics L L C Verfahren zur behandlung von virusinfektionen unter verwendung von il-28 und il-29
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer

Also Published As

Publication number Publication date
US20070048804A1 (en) 2007-03-01
PT1356046E (pt) 2010-03-09
US20140248661A1 (en) 2014-09-04
CY1110921T1 (el) 2015-06-10
WO2002044209A2 (en) 2002-06-06
US7601809B2 (en) 2009-10-13
US7618791B2 (en) 2009-11-17
WO2002044209A3 (en) 2003-08-21
US20070048846A1 (en) 2007-03-01
US20110091876A1 (en) 2011-04-21
US20070048799A1 (en) 2007-03-01
DE60140213D1 (de) 2009-11-26
EP1356046A2 (de) 2003-10-29
US20050266485A1 (en) 2005-12-01
US7608452B2 (en) 2009-10-27
AU2002241533A1 (en) 2002-06-11
US20030027253A1 (en) 2003-02-06
JP2004532611A (ja) 2004-10-28
EP1356046B1 (de) 2009-10-14
DK1356046T3 (da) 2010-03-01
CA2430485A1 (en) 2002-06-06
US20070117165A1 (en) 2007-05-24
ES2334888T3 (es) 2010-03-17
US20120064571A1 (en) 2012-03-15
US20070111942A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
DK1356046T3 (da) Cytokinreceptor zcytoR19
WO2002000721A3 (en) Cytokine receptor zcytor17
ATE456654T1 (de) Löslicher zytokinrezeptor zalpfa11
NZ510744A (en) Cytokine receptor zalpha11
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
ATE371735T1 (de) Hematopoietischer zytokin rezeptor
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
IL163067A (en) Isolated heterodimeric cytokine receptor
ATE273384T1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
WO2003089603A3 (en) Cytokine receptor
NO985904L (no) TIE-2-reseptorligander (TIE-ligand-3, TIE-ligand-4), samt anvendelse derav
HK1025793A1 (en) Hepatitis c receptor protein cd81
NO993653L (no) FremgangsmÕte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
DE60117788D1 (de) Menschliche wingless-änhliche gene
Motozawa et al. Functional comparison of high and low molecular weight basic fibroblast growth factors
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1356046

Country of ref document: EP